Tonix Pharmaceuticals
TNXP
14 hedge funds and large institutions have $1.62M invested in Tonix Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
0% more ownership
Funds ownership: 0% → 0% (+0%)
22% less funds holding
Funds holding: 18 → 14 (-4)
64% less capital invested
Capital invested by funds: $4.51M → $1.62M (-$2.89M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$98.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$60.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$53.1K |
| 4 |
Renaissance Technologies
New York
|
+$37.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$650K |
| 2 |
Morgan Stanley
New York
|
-$250K |
| 3 |
HFS
Hantz Financial Services
Southfield,
Michigan
|
-$51K |
| 4 |
JP Morgan Chase
New York
|
-$37.9K |
| 5 |
VF
Virtu Financial
New York
|
-$35K |
TNXP Hedge Fund Activity: Q2 2023 in Review
14 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q2 2023, worth a combined $1.62M — down 64% from $4.51M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TNXP and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 7 added.
The largest buyer was Acadian Asset Management, adding an estimated $98.5K. The largest seller was Tang Capital Management, exiting entirely with an estimated $650K sold.
- 14 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q2 2023, down from 18 in Q1 2023.
- Funds reported $1.62M of Tonix Pharmaceuticals stock for Q2 2023, down 64% quarter-over-quarter.
- 1 fund opened new Tonix Pharmaceuticals positions in Q2 2023 and 5 closed out, a net change of -4 holders.
- The largest Tonix Pharmaceuticals buyer in Q2 2023 was Acadian Asset Management, an estimated $98.5K added.
- The largest Tonix Pharmaceuticals seller in Q2 2023 was Tang Capital Management, an estimated $650K sold.
Based on aggregated 13F filings for Q2 2023.